To print: Select File and then Print from your browser's menu

Title: Pixantrone Combination Regimen Produces High Rates of Complete Remission for Patients With Aggressive NHL Who Fail CHOP Therapy

"Pixantrone Combination Regimen Produces High Rates of Complete Remission for Patients With Aggressive NHL Who Fail CHOP Therapy"

Preliminary Results of Phase II Trial Reported at Invest Northwest Conference SEATTLE, W.A. -- March 22, 2006 -- At the 2006 Invest Northwest conference, Cell Therapeutics, Inc. presented preliminary results of a phase 1/2 clinical trial of pixantrone in 64 patients with relapsed aggressive non-Hodgkin's lymphoma who had previously failed one or two prior chemotherapy regimens, including the CHOP regimen. The two-part study was designed to determine the maximum tolerated dose and evaluate the drug's effectiveness in a combination known as CPOP, in which pixantrone replaces doxorubicin in the standard CHOP regimen. All patients on the study had received prior doxorubicin therapy and as such were at risk for developing severe cardiac toxicity with additional anthracycline therapy. The CPOP regimen was highly effective, with complete response/unconfirmed complete response rates of 41% (14 of 34 patients) and 43% (13 of 30 patients) and overall response rates of 71% (24 of 34 patients) and 77% (23 of 30 patients) in the phase 1 and 2 component of the study, respectively. Predominant side effects were blood-related and included 60 to 75% grade 4 neutropenia and 23% febrile neutropenia. Grade 3 infections were observed at the 150 mg/m[² dose level (10%), but no grade 3 infections have been reported to date at the 180 mg/m² dose level. There was one case of congestive heart failure reported, which was felt by the investigator to be related to the patient's underlying cardiac disease.

"These data suggest that in the relapsed setting, substituting pixantrone for doxorubicin can offer patients a high probability of achieving a complete remission not available with standard chemotherapy regimens and underscores the rationale for studying the CPOP regimen versus the CHOP regimen in first-line treatment of aggressive NHL," stated James A. Bianco, MD, President and CEO of CTI. "Complete responses are the reference standard in treating non-Hodgkin's lymphoma, since it not only correlates with longer survival, but among patients who are at high risk for disease recurrence, a CR is required in order for them to undergo potentially curative bone marrow transplants."

About the CHOP Regimen
The CHOP chemotherapy regimen (a combination of cyclophosphamide, vincristine, prednisone and doxorubicin) is the standard-of-care treatment for newly diagnosed (first-line) aggressive NHL. Response rates following CHOP in first-line aggressive NHL can reach 70% and the regimen is potentially curative in up to 40% of patients.

The prognosis is poor for patients who have a recurrence of the disease (relapsed patients). Despite its impressive anti-tumor activity, CHOP cannot be used to retreat the 60 to 65% of patients who will relapse following CHOP, due to the cumulative cardiotoxicity associated with one of its constituent agents, doxorubicin; a chemotherapy agent which belongs to the anthracycline family.

The maximum lifetime recommended dose of doxorubicin ranges from 450 mg to 550 mg and this level is often reached during first-line treatment with CHOP.

About Pixantrone and the CPOP Regimen
Pixantrone is an investigational drug designed to potentially increase anti-tumor activity and decrease the potential for cardiac toxicity associated with the currently marketed anthracyclines. This trial examines the safety and potential efficacy of pixantrone when substituted for doxorubicin in the CHOP regimen among patients who have failed prior doxorubicin-containing CHOP therapy for aggressive NHL.

The CPOP regimen includes pixantrone, cyclosphosphamide, vincristine, and prednisone. Patients were treated with escalating doses of pixantrone, starting at a dose of 80 mg up to 180 mg/m².

SOURCE: Cell Therapeutics, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.